Search 

LSX is a growing influential community of senior life science decision makers, and are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. LSX is determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.

Their community helps catalyse early stage innovation through peer-to-peer education and knowledge sharing, networking, partnering and deal making to champion the most innovative and exciting ideas. LSX brings deals to life.

Medherant develops patches for transdermal drug delivery using our proprietary TEPI-Patch® technology. Key advantages of the TEPI Patch® technology over current technologies include excellent adhesion that can be tailored for up to 7-days of drug delivery, whilst still being easy and painless to remove.  

The TEPI Patch® provides a better experience for the user as it does not leave a residue or dirty mark around the patch – referred to as ‘cold flow’. No organic solvents are involved in manufacture of this drug-in-adhesive system.

As well as developing our own products, some of which have already been successfully tested in clinical studies, Medherant is working with pharmaceutical companies to develop new products. We are seeking additional partners and can offer rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of drugs of interest.

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins. 

The NIHR (National Institute for Health and Care Research) enables, funds and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.

The NIHR:

- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research

- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future

- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services

- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy. Oncimmune is headquartered in the UK with operations in Germany and USA.